A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2015 The primary endpoint has been changed from RAD001 can shrink or slow the growth of tumors to objective response plus stable disease rate along with change in assessment duration from 4 years to 8 weeks as per ClinicalTrials.gov record.
07 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
03 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as per ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com